## Francis Couturaud

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3284120/publications.pdf

Version: 2024-02-01

156 papers 5,840 citations

34 h-index 72 g-index

169 all docs

169
docs citations

169 times ranked 5229 citing authors

#	Article	IF	CITATIONS
1	Fibrinolysis for Patients with Intermediate-Risk Pulmonary Embolism. New England Journal of Medicine, 2014, 370, 1402-1411.	27.0	1,221
2	Effect of a Retrievable Inferior Vena Cava Filter Plus Anticoagulation vs Anticoagulation Alone on Risk of Recurrent Pulmonary Embolism. JAMA - Journal of the American Medical Association, 2015, 313, 1627.	7.4	404
3	Prevalence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Thrombosis and Haemostasis, 2014, 112, 598-605.	3.4	271
4	Impact of Thrombolytic Therapy onÂtheÂLong-Term Outcome of Intermediate-Risk PulmonaryÂEmbolism. Journal of the American College of Cardiology, 2017, 69, 1536-1544.	2.8	258
5	Prognostic Factors for Pulmonary Embolism. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 168-173.	5.6	208
6	Pregnancy-Adapted YEARS Algorithm for Diagnosis of Suspected Pulmonary Embolism. New England Journal of Medicine, 2019, 380, 1139-1149.	27.0	200
7	Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism. JAMA - Journal of the American Medical Association, 2015, 314, 31.	7.4	195
8	Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. BMJ: British Medical Journal, 2019, 366, 14363.	2.3	177
9	Effects of inspiratory muscle training in COPD patients: A systematic review and metaâ€analysis. Clinical Respiratory Journal, 2018, 12, 2178-2188.	1.6	146
10	High Prevalence of Asymptomatic Deep Vein Thrombosis on Admission in a Medical Unit among Elderly Patients. Thrombosis and Haemostasis, 2002, 88, 592-597.	3.4	96
11	Current incidence of venous thromboembolism and comparison with 1998: a community-based study in Western France. Thrombosis and Haemostasis, 2016, 116, 967-974.	3.4	96
12	Treatment and Long-Term Clinical Outcomes of Incidental Pulmonary Embolism in Patients With Cancer: An International Prospective Cohort Study. Journal of Clinical Oncology, 2019, 37, 1713-1720.	1.6	90
13	Limited screening with versus without 18F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial. Lancet Oncology, The, 2016, 17, 193-199.	10.7	83
14	Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial. Lancet Haematology,the, 2021, 8, e22-e33.	4.6	82
15	Echocardiography and pulmonary embolism severity index have independent prognostic roles in pulmonary embolism. European Respiratory Journal, 2013, 42, 681-688.	6.7	68
16	Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. Lancet Respiratory Medicine, the, 2019, 7, 771-779.	10.7	65
17	Triaging acute pulmonary embolism for home treatment by Hestia or simplified PESI criteria: the HOME-PE randomized trial. European Heart Journal, 2021, 42, 3146-3157.	2.2	64
18	Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism. Annals of Internal Medicine, 2021, 174, 1420-1429.	3.9	60

#	Article	IF	Citations
19	Low Molecular Weight Heparin Administered once versus twice Daily in Patients with Venous Thromboembolism. Thrombosis and Haemostasis, 2001, 86, 980-984.	3.4	59
20	Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital-based case-control study. Fundamental and Clinical Pharmacology, 2004, 18, 477-482.	1.9	59
21	Noninvasive Diagnosis of Pulmonary Embolism. Chest, 2011, 139, 1294-1298.	0.8	59
22	Factors that predict thrombosis in relatives of patients with venous thromboembolism. Blood, 2014, 124, 2124-2130.	1.4	59
23	Computed tomography pulmonary angiography <i>versus</i> ventilation-perfusion lung scanning for diagnosing pulmonary embolism during pregnancy: a systematic review and meta-analysis.  Haematologica, 2019, 104, 176-188.	3.5	56
24	Diagnosis of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. European Respiratory Journal, 2020, 55, 2000189.	6.7	55
25	Cytokine and chemokine regulation of venous thromboembolism. Journal of Thrombosis and Haemostasis, 2020, 18, 1009-1019.	3.8	53
26	Prevalence of Pulmonary Embolism Among Patients With COPD Hospitalized With Acutely Worsening Respiratory Symptoms. JAMA - Journal of the American Medical Association, 2021, 325, 59.	7.4	52
27	Factors That Predict Risk of Thrombosis in Relatives of Patients With Unprovoked Venous Thromboembolism. Chest, 2009, 136, 1537-1545.	0.8	49
28	Annexin A2 autoantibodies in thrombosis and autoimmune diseases. Thrombosis Research, 2015, 135, 226-230.	1.7	45
29	Patent Foramen Ovale and Ischemic Stroke in Patients With Pulmonary Embolism. Annals of Internal Medicine, 2019, 170, 756.	3.9	45
30	Incomplete echocardiographic recovery at 6Âmonths predicts long-term sequelae after intermediate-risk pulmonary embolism. A post-hoc analysis of the Pulmonary Embolism Thrombolysis (PEITHO) trial. Clinical Research in Cardiology, 2019, 108, 772-778.	3.3	44
31	Responsiveness and Minimally Important Difference of the 6-Minute Stepper Test in Patients with Chronic Obstructive Pulmonary Disease. Respiration, 2016, 91, 367-373.	2.6	42
32	Risk factors for recurrent venous thromboembolism after unprovoked pulmonary embolism: the PADIS-PE randomised trial. European Respiratory Journal, 2018, 51, 1701202.	6.7	42
33	Incidence of venous thromboembolism in first-degree relatives of patients with venous thromboembolism who have factor V Leiden. Thrombosis and Haemostasis, 2006, 96, 744-749.	3.4	41
34	V/Q SPECT Interpretation for Pulmonary Embolism Diagnosis: Which Criteria to Use?. Journal of Nuclear Medicine, 2013, 54, 1077-1081.	5.0	41
35	Safety of ventilation/perfusion single photon emission computed tomography for pulmonary embolism diagnosis. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1957-1964.	6.4	34
36	Additional value of combining low-dose computed tomography to V/Q SPECT on a hybrid SPECT-CT camera for pulmonary embolism diagnosis. Nuclear Medicine Communications, 2015, 36, 922-930.	1.1	34

#	Article	IF	Citations
37	Pneumocystis jirovecii in the air surrounding patients with Pneumocystis pulmonary colonization. Diagnostic Microbiology and Infectious Disease, 2015, 82, 137-142.	1.8	34
38	Hydroxychloroquine in mild-to-moderate coronavirus disease 2019: a placebo-controlled double blind trial. Clinical Microbiology and Infection, 2021, 27, 1124-1130.	6.0	34
39	Diagnostic value of D-dimer in patients with suspected pulmonary embolism: Results from a multicentre outcome study. Thrombosis Research, 2007, 120, 195-200.	1.7	33
40	Risk for Recurrent Venous Thromboembolism in Patients With Subsegmental Pulmonary Embolism Managed Without Anticoagulation. Annals of Internal Medicine, 2022, 175, 29-35.	3.9	33
41	Influence of gender on delays and early mortality in ST-segment elevation myocardial infarction: Insight from the first French Metaregistry, 2005–2012 patient-level pooled analysis. International Journal of Cardiology, 2018, 262, 1-8.	1.7	32
42	Factors predicting outcome after pulmonary endarterectomy. PLoS ONE, 2018, 13, e0198198.	2.5	29
43	The Extent of Aspergillosis in Critically Ill Patients With Severe Influenza Pneumonia: A Multicenter Cohort Study. Critical Care Medicine, 2021, 49, 934-942.	0.9	29
44	Effect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes in Patients Hospitalized for COPD Exacerbation. JAMA - Journal of the American Medical Association, 2021, 326, 1277.	7.4	28
45	High prevalence of asymptomatic deep vein thrombosis on admission in a medical unit among elderly patients. Thrombosis and Haemostasis, 2002, 88, 592-7.	3.4	28
46	Fibrinogen A $\hat{l}_{\pm}$ -Thr312Ala and factor XIII-A Val34Leu polymorphisms in idiopathic venous thromboembolism. Thrombosis Research, 2007, 121, 333-338.	1.7	26
47	Six months <i>versus</i> two years of oral anticoagulation after a first episode of unprovoked deep-vein thrombosis. The PADIS-DVT randomized clinical trial. Haematologica, 2019, 104, 1493-1501.	3.5	26
48	Validation of the French version of the London Chest Activity of Daily Living scale and the Dyspnea-12 questionnaire. International Journal of COPD, 2018, Volume 13, 1399-1405.	2.3	25
49	Thrombin generation in first-degree relatives of patients with venous thromboembolism who have factor V Leiden. Thrombosis and Haemostasis, 2008, 99, 223-228.	3.4	23
50	Comparison of Outcome of Transcatheter Aortic Valve Implantation With Versus Without Previous Coronary Artery Bypass Grafting (from the FRANCE 2 Registry). American Journal of Cardiology, 2015, 116, 420-425.	1.6	22
51	Lymphocyte Disturbances in Primary Antiphospholipid Syndrome and Application to Venous Thromboembolism Follow-Up. Clinical Reviews in Allergy and Immunology, 2017, 53, 14-27.	6.5	22
52	The prognostic value of pro-B-Type natriuretic peptide in acute pulmonary embolism. Thrombosis Research, 2013, 131, e235-e239.	1.7	21
53	Transthoracic Sonography of the Lung and Pleura in View of a Suspected Pulmonary Embolism. Journal of Ultrasound in Medicine, 2003, 22, 673-678.	1.7	20
54	Incidence of upper-extremity deep vein thrombosis in western France: a community-based study. Haematologica, 2019, 104, e29-e31.	3.5	20

#	Article	IF	CITATIONS
55	Longâ€term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and metaâ€analysis. Journal of Thrombosis and Haemostasis, 2021, 19, 2801-2813.	3.8	19
56	Performance of 18F fluoro-2-d $\tilde{A}$ @soxy-D-glucose positron emission tomography/computed tomography for the diagnosis of venous thromboembolism. Thrombosis Research, 2015, 135, 31-35.	1.7	18
57	Pitfalls in the diagnostic management of pulmonary embolism in pregnancy. Thrombosis Research, 2017, 151, S86-S91.	1.7	18
58	Real-world incidence of cancer following a first unprovoked venous thrombosis: Results from the EPIGETBO study. Thrombosis Research, 2018, 164, 79-84.	1.7	18
59	Predictors for Residual Pulmonary Vascular Obstruction after Unprovoked Pulmonary Embolism: Implications for Clinical PracticeနThe PADIS-PE Trial. Thrombosis and Haemostasis, 2019, 119, 1489-1497.	3.4	17
60	Endothelial Cell Phenotype, a Major Determinant of Venous Thrombo-Inflammation. Frontiers in Cardiovascular Medicine, 2022, 9, 864735.	2.4	17
61	Clinical Usefulness of D-Dimer Tests in Excluding Pulmonary Embolism Is Highly Dependent upon Age. Thrombosis and Haemostasis, 1998, 80, 527-527.	3.4	16
62	Risk of recurrent venous thromboembolism in COPD patients: results from a prospective cohort study. European Respiratory Journal, 2017, 50, 1700094.	6.7	16
63	Risk of venous thromboembolism in association with factor V leiden in cancer patients – The EDITH case-control study. PLoS ONE, 2018, 13, e0194973.	2.5	16
64	Apixaban and rivaroxaban in obese patients treated for venous thromboembolism: Drug levels and clinical outcomes. Thrombosis Research, 2021, 208, 39-44.	1.7	16
65	Risk factors of occult malignancy in patients with unprovoked venous thromboembolism. Thrombosis Research, 2017, 159, 48-51.	1.7	15
66	Association of common genetic variations and idiopathic venous thromboembolism. Thrombosis and Haemostasis, 2010, 103, 1161-1169.	3.4	14
67	Increased thrombin generation measured in the presence of thrombomodulin in women with early pregnancy loss. Fertility and Sterility, 2011, 95, 1813-1815.e1.	1.0	14
68	Reduction of coagulability state one year after bariatric surgery. Surgery for Obesity and Related Diseases, 2017, 13, 327-333.	1.2	14
69	Effect of Early Initiation of Varenicline on Smoking Cessation in COPD Patients Admitted for Exacerbation: The Save Randomized Clinical Trial. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2020, 17, 7-14.	1.6	14
70	Incidence of venous thromboembolism in first-degree relatives of patients with venous thromboembolism who have factor V Leiden. Thrombosis and Haemostasis, 2006, 96, 744-9.	3.4	14
71	Risk factors and clinical presentation of venous thromboembolism according to the age of relatives of patients with factor V Leiden. Thrombosis and Haemostasis, 2008, 99, 793-794.	3.4	13
72	Predictors of residual pulmonary vascular obstruction after pulmonary embolism: Results from a prospective cohort study. Thrombosis Research, 2020, 194, 1-7.	1.7	13

#	Article	IF	Citations
73	Diuretic vs. placebo in intermediate-risk acute pulmonary embolism: a randomized clinical trial. European Heart Journal: Acute Cardiovascular Care, 2022, 11, 2-9.	1.0	13
74	Quality of life in cancer patients undergoing anticoagulant treatment with LMWH for venous thromboembolism: the QUAVITEC study on behalf of the Groupe Francophone Thrombose et Cancer (GFTC). Oncotarget, 2018, 9, 26990-26999.	1.8	13
75	Frequency and incidence of arterial events in patients with venous thromboembolism compared to the general population: A systematic review and meta-analysis of cohort studies. Thrombosis Research, 2021, 203, 172-185.	1.7	12
76	Interrelation of hyperhomocysteinemia and inherited risk factors for venous thromboembolism. Results from the E.D.I.TH. study: A hospital-based case–control study. Thrombosis Research, 2007, 120, 207-214.	1.7	11
77	A Qualitative Study to Appraise Patients and Family Members Perceptions, Knowledge, and Attitudes towards Venous Thromboembolism Risk. PLoS ONE, 2015, 10, e0142070.	2.5	11
78	Diuretic versus placebo in normotensive acute pulmonary embolism with right ventricular enlargement and injury: a double-blind randomised placebo controlled study. Protocol of the DiPER study. BMJ Open, 2015, 5, e007466-e007466.	1.9	11
79	Tinzaparin and VKA use in patients with cancer associated venous thromboembolism: A retrospective cohort study. Thrombosis Research, 2015, 135, 78-83.	1.7	11
80	Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Thrombosis Research, 2017, 155, 6-9.	1.7	11
81	Evaluation of the predictive value of the bleeding prediction score VTEâ€BLEED for recurrent venous thromboembolism. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 364-371.	2.3	11
82	Outpatient Management of Patients With COVID-19. Chest, 2021, 160, 1222-1231.	0.8	11
83	Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre, single-arm, phase 4 trial. Lancet Haematology,the, 2021, 8, e627-e636.	4.6	11
84	Effect of age on the performance of a diagnostic strategy based on clinical probability, spiral computed tomography and venous compression ultrasonography. Thrombosis and Haemostasis, 2005, 93, 605-609.	3.4	10
85	Site of venous thromboembolism and prothrombotic mutations according to body mass index. Results from the EDITH study. British Journal of Haematology, 2011, 154, 486-491.	2.5	10
86	SPECT V/Q for the diagnosis of pulmonary embolism: protocol for a systematic review and meta-analysis of diagnostic accuracy and clinical outcome. BMJ Open, 2018, 8, e022024.	1.9	10
87	Impact of bariatric surgery on oral anticoagulants pharmacology, and consequences for clinical practice: a narrative review. Fundamental and Clinical Pharmacology, 2021, 35, 53-61.	1.9	10
88	Long-term recurrence risk after a first venous thromboembolism in men and women under 50 years old: A French prospective cohort. European Journal of Internal Medicine, 2021, 84, 24-31.	2.2	10
89	Comparison of 3-minute Step Test (3MStepT) and 6-minute Walk Test (6MWT) in Patients with COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2019, 16, 266-271.	1.6	9
90	The rationale, design, and methods of a randomized, controlled trial to evaluate the efficacy and safety of an active strategy for the diagnosis and treatment of acute pulmonary embolism during exacerbations of chronic obstructive pulmonary disease. Clinical Cardiology, 2019, 42, 346-351.	1.8	9

#	Article	IF	Citations
91	Long-term treatment for venous thromboembolism. Current Opinion in Hematology, 2000, 7, 302-308.	2.5	8
92	Predictors of thrombosis in relatives of patients with venous thromboembolism. Current Opinion in Pulmonary Medicine, 2010, 16, 453-458.	2.6	8
93	Evaluation of Venous Thromboembolism Recurrence Scores in an Unprovoked Pulmonary Embolism Population: A Post-hoc Analysis of the PADIS-PE trial. American Journal of Medicine, 2020, 133, e406-e421.	1.5	8
94	Pulmonary perfusion by iodine subtraction maps CT angiography in acute pulmonary embolism: comparison with pulmonary perfusion SPECT (PASEP trial). European Radiology, 2020, 30, 4857-4864.	4.5	8
95	Risk factors for recurrence during a pregnancy following a first venous thromboembolism: A French observational study. Journal of Thrombosis and Haemostasis, 2022, , .	3.8	8
96	High frequency of factor V Leiden in surgical patients with symptomatic venous thromboembolism despite prophylaxis. Thrombosis and Haemostasis, 2007, 97, 171-5.	3.4	8
97	Pneumocystis jiroveciihaplotypes at the internal transcribed spacers of the rRNA operon in French HIV-negative patients with diverse clinical presentations of Pneumocystisin fections. Medical Mycology, 2013, 51, 851-862.	0.7	7
98	Guided duration of anticoagulation after unprovoked venous thromboembolism using D-dimer testing. European Respiratory Journal, 2016, 47, 1313-1314.	6.7	7
99	The prognostic value of respiratory symptoms and performance status in ambulatory cancer patients and unsuspected pulmonary embolism; analysis of an international, prospective, observational cohort study. Journal of Thrombosis and Haemostasis, 2021, 19, 2791-2800.	3.8	7
100	Long-term risk of recurrence after discontinuing anticoagulants for a first unprovoked venous thromboembolism: protocol for a systematic review and meta-analysis. BMJ Open, 2017, 7, 016950.	1.9	6
101	Association between hospitalization for acute medical illness and VTE risk: A lower efficacy of thromboprophylaxis in elderly patients? Results from the EDITH case-control study. European Journal of Internal Medicine, 2017, 44, 39-43.	2.2	6
102	In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems. Thrombosis Research, 2018, 171, 97-102.	1.7	6
103	Thrombotic risk assessment and analytical performance of the chemiluminescent analyzer IDS-iSYS for the detection of anti-cardiolipin and anti-beta 2 glycoprotein I autoantibodies. Clinical Immunology, 2018, 194, 92-99.	3.2	6
104	Bleeding complications during pregnancy and delivery in haemophilia carriers and their neonates in Western France: An observational study. Haemophilia, 2020, 26, 1046-1055.	2.1	6
105	Acquired von Willebrand syndrome and lymphoproliferative disorders: A case report. Clinical Case Reports (discontinued), 2020, 8, 900-904.	0.5	6
106	Outcomes in patients with acute pulmonary embolism and patent foramen ovale: Findings from the RIETE registry. Thrombosis Research, 2021, 202, 59-66.	1.7	6
107	Association between statin exposure and venous thromboembolism risk in cancer patients. Data from the EDITH case-control study. European Journal of Internal Medicine, 2017, 46, e42-e44.	2.2	5
108	Thrombin Generation Measurements in Patients Scheduled for Laparoscopic Bariatric Surgery. Obesity Surgery, 2017, 27, 2015-2021.	2.1	5

#	Article	IF	CITATIONS
109	The Impact of Pulmonary Vascular Obstruction on the Risk of Recurrence of Pulmonary Embolism: A French Prospective Cohort. Thrombosis and Haemostasis, 2021, 121, 955-963.	3.4	5
110	COPD is not only one of the several VTE risk factors. European Journal of Internal Medicine, 2021, 84, 14-15.	2.2	5
111	Residual pulmonary vascular obstruction and recurrence after acute pulmonary embolism: protocol for a systematic review and meta-analysis of individual participant data. BMJ Open, 2018, 8, e023939.	1.9	4
112	Novel Anticoagulant Treatment for Pulmonary Embolism with Direct Oral Anticoagulants Phase 3 Trials and Clinical Practice. Seminars in Interventional Radiology, 2018, 35, 83-91.	0.8	4
113	Incidence of Cancer after a Second Unprovoked Venous Thromboembolic Event. Thrombosis and Haemostasis, 2019, 119, 490-495.	3.4	4
114	Meta-Analysis of Long-Term Risk of Recurrent Venous Thromboembolism after Stopping Anticoagulation in Men and Women with First Unprovoked Venous Thromboembolism. Blood, 2018, 132, 2527-2527.	1.4	4
115	Real-Life Incidence of Cancer Following a First Unprovoked Venous Thrombosis: Results from the Epigetbo Study. Blood, 2016, 128, 415-415.	1.4	4
116	Lung Ventilation/Perfusion Scintigraphy for the Screening of Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Which Criteria to Use?. Frontiers in Medicine, 2022, 9, 851935.	2.6	4
117	Whole exome sequencing, a hypothesis-free approach to investigate recurrent early miscarriage. Reproductive BioMedicine Online, 2021, 42, 789-798.	2.4	3
118	Evaluation of beta-2 microglobulin, erythropoietin and tobacco use in polycythemic cases. International Journal of Hematology, 2021, 114, 222-227.	1.6	3
119	Risk Factors of Arterial Events in Patients with Venous Thromboembolism: A Systematic Review and Meta-Analysis. Thrombosis and Haemostasis, 2021, , .	3.4	3
120	Quality of life in patients with pulmonary embolism treated with edoxaban versus warfarin. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12566.	2.3	3
121	Long-term risk of major bleeding after discontinuing anticoagulation for unprovoked venous thromboembolism: a systematic review and meta-analysis. Thrombosis and Haemostasis, 2021, 0, .	3.4	3
122	Risk Factors of Cardiovascular Death after Venous Thromboembolism: Results from a Prospective Cohort Study. Thrombosis and Haemostasis, 2022, 122, 1744-1756.	3.4	3
123	Management of suspected venous thromboembolism: the impact of a multifaceted intervention. International Journal for Quality in Health Care, 2005, 17, 433-438.	1.8	2
124	Management of suspected pulmonary embolism patients with low clinical and low $V/Q$ probability. Thrombosis Research, 2008, 122, 450-454.	1.7	2
125	Time trend analysis of pulmonary embolism diagnosis with single-photon emission computed tomography ventilation/perfusion imaging. Nuclear Medicine Communications, 2019, 40, 576-582.	1.1	2
126	A rare coding mutation in the MAST2 gene causes venous thrombosis in a French family with unexplained thrombophilia: The Breizh MAST2 Arg89Gln variant. PLoS Genetics, 2021, 17, e1009284.	3.5	2

#	Article	IF	CITATIONS
127	Effect of Local Anesthesia on Pain During Arterial Puncture: The GAEL Randomized Placebo-Controlled Trial. Respiratory Care, 2021, 66, 976-982.	1.6	2
128	Pulmonary Embolism Prevalence Among Hospitalized Patients With COPD—Reply. JAMA - Journal of the American Medical Association, 2021, 325, 1903.	7.4	2
129	Screening for COPD in primary care, involving dentists, pharmacists, physiotherapists, nurses and general practitioners (the UNANIME pilot study). Respiratory Medicine and Research, 2021, 80, 100853.	0.6	2
130	Association between obstructive sleep apnea and venous thromboembolism recurrence: results from a French cohort. Thrombosis Journal, 2022, 20, $1$ .	2.1	2
131	Recurrent venous thromboembolism under anticoagulant therapy: a high risk in adenocarcinoma?. Thrombosis and Haemostasis, 2006, 95, 912-3.	3.4	2
132	Bleeding risk of intramuscular injection of COVIDâ€19 vaccines in adult patients with therapeutic anticoagulation. Journal of Thrombosis and Haemostasis, 2022, 20, 1507-1510.	3.8	2
133	Effect of neuromuscular electrical stimulation on exercise capacity in patients with severe chronic obstructive pulmonary disease: A randomised controlled trial. Clinical Rehabilitation, 2022, 36, 1072-1082.	2.2	2
134	Postthrombotic syndrome and quality of life after deep vein thrombosis in patients treated with edoxaban versus warfarin. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12748.	2.3	2
135	Interest of chest X-ray in tailoring the diagnostic strategy in patients with suspected pulmonary embolism. Blood Coagulation and Fibrinolysis, 2015, 26, 643-648.	1.0	1
136	Treatment of pulmonary embolism. Presse Medicale, 2015, 44, e393-e399.	1.9	1
137	Therapeutic management of acute pulmonary embolism. Expert Review of Respiratory Medicine, 2017, 11, 641-648.	2.5	1
138	Patent Foramen Ovale and Ischemic Stroke in Patients With Pulmonary Embolism. Annals of Internal Medicine, 2019, 171, 527.	3.9	1
139	Risk of recurrent venous thromboembolism and bleeding in patients with interstitial lung disease: a cohort study. Journal of Thrombosis and Thrombolysis, 2022, 53, 67-73.	2.1	1
140	Risk factors of arterial thrombotic events after unprovoked venous thromboembolism, and after cancer associated venous thromboembolism: A prospective cohort study. Thrombosis Research, 2022, 214, 93-105.	1.7	1
141	Risk Factors for Major Adverse Cardiovascular Events and Major Adverse Limb Events after Venous Thromboembolism: A Large Prospective Cohort Study. Seminars in Thrombosis and Hemostasis, 2022, 48, 465-480.	2.7	1
142	A case of avian influenza (H5N1) pulmonary infection with early expansion of lung bulla formations. Respiratory Medicine Extra, 2005, 1, 61-64.	0.1	0
143	Cas clinique à tendance thérapeutique n°6. Revue Des Maladies Respiratoires Actualites, 2012, 4, 73-74.	0.0	0
144	Breathlessness measurement should be standardised for the level of exertion. European Respiratory Journal, 2018, 51, 1800820.	6.7	0

#	Article	IF	CITATIONS
145	Cas clinique n° 6. Revue Des Maladies Respiratoires Actualites, 2019, 11, 38-39.	0.0	O
146	Cas clinique $n\hat{A}^{\circ}$ 6 : Embolie pulmonaire : place du bilan de thrombophilie et impact sur la prise en charge. Revue Des Maladies Respiratoires Actualites, 2019, 11, 40-42.	0.0	0
147	Effect of different form of upper limb muscles training on dyspnea in chronic obstructive pulmonary disease. Medicine (United States), 2020, 99, e22131.	1.0	0
148	A 60-Year-Old Woman With Recurrent Hemoptysis. Chest, 2020, 158, e273-e277.	0.8	0
149	A case of acute pulmonary embolism with severe haemoptysis. Thrombosis Research, 2021, , .	1.7	0
150	Age May Modify the Relationship between Factor V Leiden Mutation - but Not G20210A Prothrombin Gene Variation - and Idiopathic Venous Thromboembolism: An Hospital-Based Case-Control Study Blood, 2004, 104, 4052-4052.	1.4	0
151	Risk of Recurrence of Venous Thromboembolism After Major Surgery for Cancer,. Blood, 2011, 118, 3342-3342.	1.4	0
152	La maladie veineuse thrombo-embolique et trombo-philie héréditaire. Bulletin De L'Academie Nationale De Medecine, 2015, 199, 987-989.	0.0	0
153	Association Between Hospitalization for Acute Medical Illness and VTE Risk: A Lower Efficacy of Thromboprophylaxis in Elderly Patients? Results from the Edith Case-Control Study. Blood, 2015, 126, 2326-2326.	1.4	0
154	Quality of Life in Cancer Patients Undergoing Anticoagulant Treatment for Venous Thromboembolism: The Quavitec Study. Blood, 2016, 128, 880-880.	1.4	0
155	Safety and Efficiency of the YEARS Diagnostic Algorithm for Pregnant Patients with Clinically Suspected Acute Pulmonary Embolism —the Artemis Study. Blood, 2018, 132, 419-419.	1.4	0
156	Use of Anticoagulants of Patients with Cancer-Associated Thrombosis Beyond 6 Months; The Uscat Study, a 432-Patient Retrospective Non-Interventional Study. Blood, 2019, 134, 3664-3664.	1.4	0